BridgeMD
The effect of oral folinic acid to prevent pemetrexed induced adverse events.
EU CTIS ID: 2022-502345-10-00
What this study is testing
The main objective is to evaluate the haematological toxicity in patients who use pemetrexed with and without rescue therapy with folinic acid.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ≥18 years old
- Eligible for treatment with pemetrexed-based chemotherapy based on indication.
- ECOG performance score of 0-2.
- Subject is able and willing to sign the Informed Consent Form.
You likely can't join if
- Contraindications for treatment with folinic acid in line with the SmPC. a. Hypersensitivity to the active substance or to any of the excipients. b. Anaemia caused by vitamin B12 deficiency.
- The presence of clinically relevant drug-drug interactions, according to the current SmPC of folinic acid.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.